Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study
Lothar Bergmann(Universität Ulm), Christian Doehn(University of Lübeck), Manfred Kindler(Praxis), Thomas Steiner(Helios Klinikum Erfurt), Friedrich Overkamp, Andreas Jakob(Offenburg University of Applied Sciences), Joerg Schmitz(Springer Nature (Germany)), Ulrich Kube(Goethe Institut), Peter J. Goebell(Friedrich-Alexander-Universität Erlangen-Nürnberg), Gernot Guderian(University of Basel), Michael Staehler(München Klinik), Edwin Herrmann(St. Jude Children's Research Hospital), Gabriel Steiner, Michael Albrecht(Novartis (Germany)), Steffen Weikert(St. Hedwig-Krankenhaus), Jan Janßen
Cited by 15
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome
|Blood|1997|352
Plk4 <i>trans</i>-autophosphorylation regulates centriole number by controlling βTrCP-mediated degradation
|Journal of Cell Science|2010|220